Session » 4M098: Vasculitis – Non-ANCA-Associated & Related Disorders II: Large Vessel Vasculitis Treatment (1836–1841)
- 2:30PM-4:00PM
-
Abstract Number: 1836
Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial
- 2:30PM-4:00PM
-
Abstract Number: 1839
Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis
- 2:30PM-4:00PM
-
Abstract Number: 1841
Resolution of Vascular Inflammation in Patients with Giant Cell Arteritis Receiving Glucocorticoids, Methotrexate or Tocilizumab Treatment: Data from the Italian/German RIGA Study
- 2:30PM-4:00PM
-
Abstract Number: 1840
Risk Factors for Treatment Failure in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone versus Prednisone Alone
- 2:30PM-4:00PM
-
Abstract Number: 1838
Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial
- 2:30PM-4:00PM
-
Abstract Number: 1837
Ustekinumab for the Treatment of Giant Cell Arteritis